Alpha Blue Capital美國中小型股動態主動型ETF ABCS 深 滬
已收盤 07-02 16:00:00 美东时间
34.1029
+0.295
+0.87%
華盛通- 最 高34.13
- 今 開33.99
- 成交量 2017股
- 最 低 33.99
- 昨 收 33.8075
- 總市值 1193.60万
- 52周最高 34.13
- 市盈率 靜 --
- 換手率 0.58%
- 52周最低 27.7946
- 委 比 0.00%
- 總股本 35.00万
- 歷史最高 34.13
- 量 比 1.11
- 振 幅 0.41%
- 歷史最低 23.4152
- 每 手 1
- 風險率 1.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Natera Announces Enrollment Of First Patients In SIGNAL-ER 101, A Prospective Study Evaluating Signatera MRD-Guided De-Escalation In Early-Stage Breast Cancer
The current standard of care recommends two or three years of an adjuvant CDK4/6 inhibitor in combination with endocrine therapy for patients with intermediate-risk, hormone receptor (HR) positive, HER2 negative, early
05-28 18:05
ALX Oncology Holdings Announces New Data Supporting Phase 1b/2 Clinical Trial For Evoracept In Combination With Jazz Pharmaceutical's Zanidatamab For Patients With Pre-Treated HER2-Positive Metastatic Breast Cancer
The Phase 1b/2 open-label, multi-center clinical trial (NCT05027139) evaluating evorpacept plus zanidatamab included patients with heavily pre-treated HER2-positive mBC (median of five prior HER2-targeted therapies), all
05-07 20:06
Actinium Pharma Presents Preclinical Results For ATNM-400 Across Prostate, Lung, And Breast Cancer Models Presented At AACR Annual Meeting
ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potentialIn prostate cancer, ATNM-400 demonstrates efficacy across both high
04-22 19:06
BridgeBio Oncology Therapeutics Launches Phase 1 Trial of BBO-10203 in Advanced Solid Tumors
BridgeBio Oncology Therapeutics Inc. announced late-breaking preclinical data on BBO-10203, a first-in-class covalent small molecule RAS:PI3Kα breaker, at the San Antonio Breast Cancer Symposium (SABC...
2025-12-11 05:05
Caris Life Sciences Unveils 19 New Breast Cancer Studies at 2025 SABCS
Caris Life Sciences Inc. announced that it will present 19 studies at the upcoming 2025 San Antonio Breast Cancer Symposium (SABCS), scheduled for December 9-12, 2025. The studies, conducted in collab...
2025-12-04 21:30
BRIEF-ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Dec 1 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A: ACTINIUM PHARMACEUTICALS ANNOUNCES ATNM-400 DATA DEMONSTRATING POTENT EFFICACY IN TRIPLE-NEGATIVE BREAST CANCER AND ABILITY TO OVERCOME ENDOCRINE...
2025-12-01 21:52
Olema Pharma Q3 net loss widens
Overview Olema reports Q3 net loss of $42.2 mln due to increased R&D expenses Company ends Q3 with $329 mln in cash and marketable securities Announced clinical trial agreement with Pfizer for palazes...
2025-11-10 20:15
Actinium Pharmaceuticals Unveils Promising ATNM-400 Data for Drug-Resistant Breast Cancer at SABCS 2025
Actinium Pharmaceuticals Inc. announced that new preclinical data for its lead antibody radioconjugate program, ATNM-400, will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS), sch...
2025-11-04 20:30
Alpha Blue Capital Management LP Enters Active ETF Space: Launches Alpha Blue Capital US Small-Mid Cap Dynamic ETF
GREENBRAE, Calif., Dec. 19, 2023 /PRNewswire/ -- Alpha Blue Capital Management LP is pleased to announce the launch of Alpha Blue Capital US Small-Mid Cap Dynamic ETF listed on the NASDAQ wi...
2023-12-19 22:15
